Cutting-edge insights: line-field confocal optical coherence tomography and 5% cyclosporine for early lichen sclerosus treatment

Atrophic lichen sclerosus (ALS) is a chronic inflammatory dermatosis with significant morbidity, primarily affecting the genital area. The disease is often misdiagnosed or underdiagnosed, resulting in delayed treatment and progression to atrophic stages and permanent scars.1 While corticosteroids remain the first-line treatment, their long-term use may lead to adverse effects such as skin Cyclosporine, a calcineurin inhibitor, has shown efficacy in managing immune-mediated skin diseases and is delivered effectively This study investigates the clinical and structural outcomes of 5% outcome has been evaluated not only clinically but also by line